Home › Companies › Adaptimmune Therapeutics

Adaptimmune Therapeutics (ADAPY) proxy voting records

How asset managers voted at Adaptimmune Therapeutics’s shareholder meetings, one page per proxy season, compiled from the votes funds and managers report on SEC Form N-PX and the company’s own results on Form 8-K.

• TickerADAPY
• CUSIP issuer number00653A
• SEC CIK1621227

Recent shareholder votes

• May 29, 2025 annual meeting (2024-2025 proxy season): 12 items in Adaptimmune Therapeutics's official results (Form 8-K, filed May 29, 2025); lowest support 94% of votes cast (Ordinary Resolution to re-elect Dr. Ali Behbahani as a Director). Full results and how funds voted.
• May 14, 2024 annual meeting (2023-2024 proxy season): 14 items in Adaptimmune Therapeutics's official results (Form 8-K, filed May 14, 2024); lowest support 95% of votes cast (Ordinary Resolution to approve, on a non-binding, advisory…). Full results and how funds voted.

Each line is the company’s own Form 8-K tally as shown on that season’s page; support is FOR as a share of votes cast.

Proxy seasons

Earlier seasons list this company under the name ADAPTIMMUNE THERAPEUTICS PLC, as its holders filed it.

Explore Adaptimmune Therapeutics in the interactive database

The seasons are grouped by the issuer number in the company’s CUSIP, not by its name. Ticker as listed by the SEC on November 6, 2026. This page is rebuilt weekly; built November 9, 2026.